A lingering headache. A body that feels heavier than usual. Small changes that are easy to ignore in a busy life. Most people brush these signs aside, trusting they will pass.
But researchers are increasingly focused on what happens when they don’t and whether unexpected tools could help.
A surprising approach
A team at the University of Calgary is testing whether vitamin B3 could support treatment for glioblastoma, one of the most aggressive brain cancers.
According to findings published in the Journal of Neuro-Oncology, early clinical data suggests the vitamin may enhance existing therapies.
Also read: Scientists study the relationship between coffee and fatty liver disease
Glioblastoma remains notoriously difficult to treat. Standard care typically combines surgery, radiation, and chemotherapy, yet relapse is common.
As reported by researchers at the university, survival outcomes have seen little improvement over the past 20 years.
Immune system focus
The study, led by oncologist Dr. Gloria Roldan Urgoiti and neuroscientist Dr. Wee Yong, centers on the immune system’s role.
Their research indicates the cancer can suppress immune activity, making it harder for the body to fight back.
Also read: Early childhood signs linked to Tourette’s syndrome
By introducing controlled doses of niacin, the team aims to restore immune cell function. Earlier laboratory work in mice showed extended survival, which led to trials in human patients.
According to the study data, early results showed:
- 82 percent of participants had no disease progression after six months
- This reflects an improvement of roughly 28 percent compared with historical benchmarks
Proceeding carefully
Despite these findings, the researchers emphasize that the treatment is still experimental.
High-dose vitamin use can carry risks and requires strict medical oversight, as highlighted in the study.
Also read: Non-drug therapies show promise for osteoarthritis
While it is too early to draw firm conclusions, the work points to a new direction in a field where breakthroughs have been rare.
Source: Scitechdaily
Also read: Study finds 31% reduction in first heart attacks with cholesterol drug